4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamide salts: Novel hydrosoluble prodrugs of antimitotics selectively bioactivated by the cytochrome P450 1A1 in breast cancer cells

• Published in: Bioorganic chemistry 2023-11, Vol.140, p.106820-106820, Article 106820
• Main Authors: Ouellette, Vincent, Chavez Alvarez, Atziri Corin, Bouzriba, Chahrazed, Hamel-Côté, Geneviève, Fortin, Sébastien
• Format: Article
• Language: English
• Subjects: 4-(2-Oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides; 4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides; Anticancer agents; Antimicrotubule agents; Antimitotics; CYP1A1-activated prodrugs; Hydrosoluble salts; PAIB-SAs; PIB-SAs
• ISSN: 0045-2068; 1090-2120
• DOI: 10.1016/j.bioorg.2023.106820

[Display omitted] •PAIB-SA salts were designed and synthesized as antimitotic prodrugs.•PAIB-SA salts exhibit a much higher hydrosolubility than their neutral counterparts.•They show high antiproliferative activity on breast cancer cells expressing CYP1A1.•They block cell cycle progression in G2/M phase and disrupt the cytoskeleton.•Salt 1 is bioactivated by CYP1A1 into its potent PIB-SA antimitotic metabolite. 4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides (PAIB-SAs) are members of a new family of prodrugs bioactivated by cytochrome P450 1A1 (CYP1A1) in breast cancer cells into their potent 4-(2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamide metabolites (PIB-SAs). One of the predominant problems for the galenic formulation and administration of PAIB-SAs in animal studies is their poor hydrosolubility. To circumvent that difficulty, we report the design, the synthesis, the chemical characterization, the evaluation of the aqueous solubility, the antiproliferative activity and the mechanism of action of 18 new Na+, K+ and Li+ salts of PAIB-SAs. Our results evidenced that the latter exhibited highly selective antiproliferative activity toward MCF7 and MDA-MB-468 breast cancer cells expressing endogenously CYP1A1 compared to insensitive MDA-MB-231 and HaCaT cells. Moreover, PAIB-SA salts 1–18 are significantly more hydrosoluble (3.9–9.4 mg/mL) than their neutral counterparts (< 0.0001 mg/mL). In addition, the most potent PAIB-SA salts 1–3 and 10–12 arrested the cell cycle progression in the G2/M phase and disrupted the cytoskeleton’s dynamic assembly. Finally, PAIB-SA salts are N-dealkylated by CYP1A1 into their corresponding PIB-SA metabolites, which are potent antimitotics. In summary, our results show that our water-soluble PAIB-SA salts, notably the sodium salts, still exhibit potent antiproliferative efficacy and remain prone to CYP1A1 bioactivation. In addition, these PAIB-SA salts will allow the development of galenic formulations suitable for further biopharmaceutical and pharmacodynamic studies.